Lebanon Pharmaceuticals and Healthcare Report Q4 2016

Publisher Name :
Date: 14-Sep-2016
No. of pages: 78

BMI View: Growth in Lebanon's pharmaceutical market will be heavily driven by the sales of high-value

prescription medicines thanks to an aging population, relatively high per capita spending and rising disease

burden. Furthermore, the Health Ministry's recent move to increase healthcare coverage for citizens over

the age of 64 highlights the country's commitment to improving healthcare quality and access across the

country. However, ongoing regional instability and Lebanon's own economic stagnation will continue to

dampen multinational drugmakers' interest in the market.

Headline Expenditure Projections

? Pharmaceuticals: LBP2.47trn (USD1.64bn) in 2015 to LBP2.60trn (USD1.72bn) in 2016; +5.5% in

local currency and US dollar terms. Forecast revised downwards slightly from last quarter.

? Healthcare: LBP5.04trn (USD3.34bn) in 2015 to LBP5.27trn (USD3.50bn) in 2016; +4.8% in local

currency and US dollar terms. Forecast unchanged from last quarter.

Lebanon Pharmaceuticals and Healthcare Report Q4 2016

Table of Contents

BMI Industry View 7
Table: Headline Pharmaceuticals & Healthcare Forecasts (Lebanon 2014-2020) 7
SWOT 9
Industry Forecast 11
Pharmaceutical Market Forecast 11
Table: Pharmaceutical Sales, Historical Data And Forecasts (Lebanon 2012-2020) 13
Healthcare Market Forecast 14
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Lebanon 2012-2020) 16
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Lebanon 2012-2020) 16
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Lebanon 2012-2020) 17
Prescription Drug Market Forecast 18
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Lebanon 2012-2020) 19
Patented Drug Market Forecast 20
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Lebanon 2012-2020) 21
Generic Drug Market Forecast 22
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Lebanon 2012-2020) 24
OTC Medicine Market Forecast 25
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Lebanon 2012-2020) 26
Pharmaceutical Trade Forecast 27
Table: Pharmaceutical Trade Data And Forecasts (Lebanon 2014-2020) 30
Table: Pharmaceutical Trade Data And Forecasts local currency (Lebanon 2014-2020) 30
Industry Risk/Reward Index 31
Middle East and Africa Risk/Reward Index - Q4 2016 31
Lebanon Risk/Reward Index 39
Rewards 39
Risks 39
Regulatory Review 41
Regulatory Developments 41
Counterfeit Drugs 43
Public Sector Procurement 43
Intellectual Property Issues 44
Free Trade Agreements 45
Pricing Regime 46
Reimbursement Regime 48
Market Overview 49
Healthcare Sector 50
Medical Tourism 53
Regional Healthcare Collaboration 54
Clinical Trials 55
Epidemiology 56
Competitive Landscape 58
Research-Based Industry 58
Table: Multinational Market Activity 59
Generic Drugmakers 59
Pharmaceutical Distribution 60
Pharmacy Retail Sector 61
Company Profile 62
Algorithm 62
Pharmaline 64
Demographic Forecast 67
Table: Population Headline Indicators (Lebanon 1990-2025) 68
Table: Key Population Ratios (Lebanon 1990-2025) 68
Table: Urban/Rural Population & Life Expectancy (Lebanon 1990-2025) 69
Table: Population By Age Group (Lebanon 1990-2025) 69
Table: Population By Age Group % (Lebanon 1990-2025) 70
Glossary 72
Methodology 74
Pharmaceutical Expenditure Forecast Model 74
Healthcare Expenditure Forecast Model 74
Notes On Methodology 75
Risk/Reward Index Methodology 76
Index Overview 77
Table: Pharmaceutical Risk/Reward Index Indicators 77
Indicator Weightings 78

List of Tables

Table: Headline Pharmaceuticals & Healthcare Forecasts (Lebanon 2014-2020)
Table: Pharmaceutical Sales, Historical Data And Forecasts (Lebanon 2012-2020)
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Lebanon 2012-2020)
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Lebanon 2012-2020)
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Lebanon 2012-2020)
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Lebanon 2012-2020)
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Lebanon 2012-2020)
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Lebanon 2012-2020)
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Lebanon 2012-2020)
Table: Pharmaceutical Trade Data And Forecasts (Lebanon 2014-2020)
Table: Pharmaceutical Trade Data And Forecasts local currency (Lebanon 2014-2020)
Table: Multinational Market Activity
Table: Population Headline Indicators (Lebanon 1990-2025)
Table: Key Population Ratios (Lebanon 1990-2025)
Table: Urban/Rural Population & Life Expectancy (Lebanon 1990-2025)
Table: Population By Age Group (Lebanon 1990-2025)
Table: Population By Age Group % (Lebanon 1990-2025)
Table: Pharmaceutical Risk/Reward Index Indicators
  • Healthy Diet Demand In Developed Economies To Boost Nutraceuticals
    As customers scuffle to keep up with the frantic lifestyles, the necessity for healthy nutrition rises owing to dearth of time to spend on laborious exercises.  Customers are shifting their attention to swift and healthy food behaviours. Increase in intake of beverages and functional food has offered makers of nutraceuticals with money-spinning prospects to benefit [...]
  • World Economic Forum Unveils Top 10 Emerging Technologies of 2016
    The World Economic Forum (WEF) and Scientific American lately unveiled the major technological innovation list of the top ten emerging technologies of 2016. This list emphasizes on the technological developments which have the supremacy to transform industries, protect the planet, and improve lives. It also presents an opening to discuss any societal, human, economic or [...]
  • Siemens Adds To the Growth of Wind Power Generation Market
    Siemens has been presenting ground-breaking strategies and pioneering solutions for energy generation for an intelligent power supply globally. With an expansive portfolio and wide-ranging proficiency in wind power generation, Siemens is likely to aid in increasing the share of wind power in the US energy mix. With New Mexico’s vicinity to significant wind energy areas, [...]
  • Global Public Safety LTE Ecosystem Overview
    In view of its flourishing ecosystem, spectrum flexibility and performance metrics, LTE has emerged as the leading candidate for public safety mobile broadband networks. Public safety organizations and establishments have already begun planning to advance their networks to LTE-based public safety solutions. LTE provisions a varied range of services, from high bandwidth data services to [...]
  • RnR Market Research: Biochips Market Insights
    Growing R&D investment and subcontracting of pharmaceutical companies would lead to growth in biochips market in Asia along with an increase in the application of biochips products is estimated to improve opportunity for the global biochip market. Conversely, the high cost involved in manufacturing of biochips can be seen as a challenge for the same. [...]
  • Iraq Pharmaceuticals and Healthcare Report Q4 2016
    Published: 21-Sep-2016        Price: US 1295 Onwards        Pages: 68
    BMI View: Iraq's ailing domestic landscape will dampen investor confidence in the country's pharmaceuticals and healthcare sectors over at least the next few years if not longer. Although the government remains committed to healthcare provision, economic and security headwinds will mean international support will remain key to ensuring the population's access to healthcare. Indeed, the domestic sector's capabilities will remain limited for the foreseeable future. The Iraq......
  • Oman Pharmaceuticals and Healthcare Report Q4 2016
    Published: 21-Sep-2016        Price: US 1295 Onwards        Pages: 75
    BMI View: The Oman Ministry of Health's decision to postpone the latest phase of medicine price reductions highlights the opaque nature of the country's pharmaceutical sector. Over the long term, Oman's population will benefit from more affordable healthcare services as even more medicines are reduced in price, however the impact on drugmaker's profit margins will continue to come under question. Nonetheless, Oman's evolving demographic and epidemiological profile will ac......
  • Pakistan Pharmaceuticals and Healthcare Report Q4 2016
    Published: 21-Sep-2016        Price: US 1295 Onwards        Pages: 108
    BMI View: Pakistan's pharmaceutical market will remain a low priority for innovative drugmakers. Downward price pressures on pharmaceutical prices coupled with uncertainty surrounding the country's policy direction impinge on potential commercial opportunities, while a fragmented procurement system hinders efforts to establish sales strategy. These factors result in an unattractive medicines market that will incentivise multinational pharmaceutical firms to invest in othe......
  • Puerto Rico Pharmaceuticals and Healthcare Report Q4 2016
    Published: 21-Sep-2016        Price: US 1295 Onwards        Pages: 91
    BMI View: An expected increase in US government funding to strengthen Puerto Rico's healthcare system will support pharmaceutical and healthcare sector growth in the commonwealth over the next few years. While the US administration will continue to seek legislative removal of Puerto Rico's Medicaid funding limitations over the coming months, the increasing risk posed by the Zika virus outbreak in the territory will push for a rise in healthcare funding to become a priorit......
  • Serbia Pharmaceuticals and Healthcare Report Q4 2016
    Published: 21-Sep-2016        Price: US 1295 Onwards        Pages: 81
    BMI View: Serbia will remain an unattractive market for multinational drugmakers in comparison to its regional neighbours. Government cost-containment, via severe drug price cuts, and continued economic issues will dampen the country's growth outlook. Headline Expenditure Projections Pharmaceuticals: RSD91.42bn (USD840mn) in 2015 to RSD88.08bn (USD766mn) in 2016; -3.7% in local currency terms and -8.8% in US dollar terms. Forecast unchanged from Q316. Healthca......
  • Singapore Pharmaceuticals and Healthcare Report Q4 2016
    Published: 21-Sep-2016        Price: US 1295 Onwards        Pages: 104
    BMI View: The delivery of healthcare in Singapore will continue to change as the country looks to deepen the integration of technology with its medical sector. This will see a shift in the flow of patients seeking medical services, their interaction with physicians and potentially the use of pharmaceuticals as mobile applications play a greater role. Consequently, drugmakers will have to adapt their marketing strategies to account for these shifts in the patient journey t......
  • Sudan and South Sudan Pharmaceuticals and Healthcare Report Q4 2016
    Published: 21-Sep-2016        Price: US 1295 Onwards        Pages: 59
    BMI View: Economic and political challenges will continue to undermine growth within Sudan and South Sudan's pharmaceutical and healthcare markets. As such, political instability will remain a barrier to any significant investment in the sector, whilst disagreements about oil revenue sharing will affect both governments' abilities to fund new healthcare infrastructure projects. The governments' plans to improve domestic pharmaceutical manufacturer capabilities will attemp......
  • Sweden Pharmaceuticals and Healthcare Report Q4 2016
    Published: 21-Sep-2016        Price: US 1295 Onwards        Pages: 98
    BMI View: Declining government reimbursement for prescription medicines and the promotion of lowervalue generic medicines does not bode well for innovative drugmakers selling their products in Sweden, particularly as the government is the primary purchaser of pharmaceuticals. Over the long term, pushing costs onto a population with fewer young people to financially support the elderly will ultimately work to reduce the consumption of higher-value innovative pharmaceutical......
  • Switzerland Pharmaceuticals and Healthcare Report Q4 2016
    Published: 21-Sep-2016        Price: US 1295 Onwards        Pages: 76
    BMI View: Switzerland will remain amongst the wealthiest countries in the world in real GDP per capita terms, which together with an aging population and a preference for patented medicines, will keep pharmaceutical spending high. However, faced with growing healthcare costs, the Swiss government will to continue to enforce measures that restrict growth in medicine sales - including the roll-out of initiatives that enforce the cost effective pricing and rational prescribi......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs